Regeneron Pharmaceuticals (REGN) closed at $818.77 on October 29, 2026, up 0.7% from the previous close, on volume of 749,760 shares (30-day average 713,176).
Data as of October 29, 2026.
29-Oct-2026
Regeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M
Seeking Alpha News (Fri, 30-Oct 6:32 AM ET)
Regeneron Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire (Fri, 30-Oct 6:30 AM ET)
Regeneron (REGN) Receives a Hold from RBC Capital
TipRanks (Thu, 29-Oct 9:47 PM ET)
Here are the major earnings before the open Friday
Seeking Alpha News (Thu, 29-Oct 6:00 PM ET)
Sanofi and Regeneron Advance Dupixent Coformulation in Key Phase 1 Study
TipRanks (Thu, 29-Oct 12:30 PM ET)
Regeneron Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Thu, 29-Oct 11:17 AM ET)
Sandoz falls as headwinds in Germany prompt cautious outlook
Seeking Alpha News (Wed, 28-Oct 1:06 PM ET)
Analysts Are Bullish on These Healthcare Stocks: Bioventus (BVS), Regeneron (REGN)
TipRanks (Wed, 28-Oct 7:51 AM ET)
Kiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst
Seeking Alpha News (Tue, 27-Oct 11:43 AM ET)
Globe Newswire (Mon, 26-Oct 7:00 AM ET)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.
As of October 29, 2026, REGN stock price climbed to $818.77 with 749,760 million shares trading.
REGN has a beta of -0.03, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.00 to the broad based SPY ETF.
REGN has a market cap of $84.30 billion. This is considered a Large Cap stock.
Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $14.29 earnings per share. This beat revenue expectation by $477 million and exceeded earnings estimates by $3.95.
In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.
The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.
REGN has outperformed the market in the last year with a price return of +26.0% while the SPY ETF gained +13.0%. REGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.9% and +2.8%, respectively, while the SPY returned +5.7% and -0.3%, respectively.
REGN support price is $798.74 and resistance is $827.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.
